FREENOME INC
FRNMNASDAQTrading Snapshot
- Day Range
- $15.88 – $16.20
- 52-Week Range
- $9.95 – $17.50
- Volume
- $2.11B
- Avg Volume
- $1.61B
- Shares Outstanding
- 8.2M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $18M
- Last Q Revenue
- $5M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own FRNM
- ✓High-growth profile — revenue up +50.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 64% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
FREENOME INC
FRNM
StockOtter · stockotter.spaceAbout FREENOME INC
Perceptive Capital Solutions Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Joseph Eric Edelman, Adam Leo Stone, and Michael R. Altman on March 22, 2024 and is headquartered in New York, NY.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition
Freenome is rated Buy, leveraging FDA-approved SimpleScreen CRC and a $410M cash reserve to target the vast unscreened colorectal market. FRNM's SimpleScreen CRC, now out-licensed to Abbott, offers a patient-friendly, bl
FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and Drug Administration (FDA
FDA approves Freenome's blood test for colorectal cancer screening
The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott to launch it in the U.S. this fall, the companies said on Monday.
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based col
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
– Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 – – Gross proceeds to Freenome totaled more than $300 million through a PIPE, led by Percepti